Tags : Antibiotics

ViewPoints Article: COVID-19 Treatment in India and Abroad

In late 2019, a mysterious virus causing infection consisting of dry cough, fever tiredness, and last pneumonia first appeared in Wuhan, China. The world health organization (WHO) named the disease as Coronavirus 2019 (Covid-19). Interestingly, Covid-19 and flu (caused by influenza virus) share the common disease progression asymptomatic (no symptoms), mild symptoms fever or chills, […]Read More

Brii Biosciences Collaborates with Qpex to Develop and Commercialize Antibiotics

Shots: Qpex Biopharm to receive up front, development, regulatory and commercial milestones with royalties on sales in the licensed territories. Brii Biosciences to get the license to develop, manufacture, and commercialize Qpex’s antibiotic portfolio in China including Taiwan, Hong Kong, Macau and the People’s Republic of China The Qpex’s portfolio includes OMNIvance, ORAvance and a […]Read More

Nosopharm Signs an Agreement with Evotec to Accelerate the Development

Shots: Nosopharm and Evotec collaborated to advance Nosopharm’s NOSO-502 to clinical stage and to develop second-generation Odilorhabdin (ODLs) for hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP), under the name NOSO-2G The collaboration initially focuses on Chemistry, Manufacturing and Control (CMC) and Clinical Trial Application (CTA)-enabling and filing activities regarding NOSO-502 for the onset of P-I study […]Read More

Eli Lilly to Sell Rights for its Two Antibiotics and

Shots: Eli Lilly to receive $75M upfront & $300M on the completion of transaction. Eddingpharm to get exclusive rights for Lilly’s two antibiotics, Ceclor and Vancocin and a manufacturing facility located in China producing Ceclor. The transaction is expected to close in H2’19/H1’20 Additionally, all the employees at the Ceclor’s manufacturing facility will continue to […]Read More

Evotec and GARDP Collaborates to Develop Novel Antibiotics for Antimicrobial

Shots: Evotec and GARDP enter into an agreement to develop novel therapies for growing   threat of antimicrobial resistance (AMR)  The focus of the collaboration is to combine GARDP’s clinical expertise with Evotec’s drug discovery platform to develop antibiotics for AMR and establish antibiotic discovery, development platform with portfolio of antibiotic assets Evotec’s anti-infective platform enabling […]Read More